89bio, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, CA, dedicated to developing and delivering innovative therapies for patients with liver and cardiometabolic diseases. Guided by the medical need of patients with limited treatment options, they utilize their expertise in FGF21 to develop meaningful medicines that have the potential to change lives.
With a focus on moving promising science forward, 89bio, Inc. is actively seeking talented individuals to join their team and contribute to their pipeline of innovative therapies, aimed at improving the lives of patients in need.
Generated from the website